Rydex Health Care C (RYHCX)
27.20
+0.26 (+0.97%)
USD |
May 20 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 2.45% | 29.00M | 0.00% | 256.0% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -2.825M | -5.93% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. The fund also may purchase American Depositary Receipts ("ADRs") to gain exposure to foreign Health Care Companies and U.S. government securities. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | RYHIX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Rydex Funds |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Michael Byrum | 24.05 yrs |
| Ryan Harder | 14.14 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
34
-2.825M
-3.360B
Category Low
9.492B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UnitedHealth Group Inc | 3.32% | 485.73 | 1.50% |
| Johnson & Johnson | 3.27% | 176.98 | 1.75% |
| AbbVie Inc | 2.58% | 151.01 | -0.47% |
| Eli Lilly and Co | 2.51% | 298.85 | 4.39% |
| Pfizer Inc | 2.51% | 52.47 | 3.59% |
| Thermo Fisher Scientific Inc | 2.31% | 555.15 | 0.80% |
| Merck & Co Inc | 2.22% | 93.55 | 1.59% |
| Danaher Corp | 2.20% | 251.80 | 1.00% |
| Abbott Laboratories | 2.14% | 113.24 | 0.71% |
| Medtronic PLC | 1.95% | 102.53 | -0.21% |
Basic Info
| Investment Strategy | |
| The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. The fund also may purchase American Depositary Receipts ("ADRs") to gain exposure to foreign Health Care Companies and U.S. government securities. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | RYHIX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Rydex Funds |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Michael Byrum | 24.05 yrs |
| Ryan Harder | 14.14 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-20-22) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield (5-19-22) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 0.0466 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of April 30, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 3/30/2001 |
| Last Annual Report Date | 3/31/2021 |
| Last Prospectus Date | 8/1/2021 |
| Share Classes | |
| RYHAX | Adv |
| RYHEX | A |
| RYHIX | Inv |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |